المؤلفون: Cerana, S, Dictar, MO, Bonvehi, P, Tregnaghi, JP, Fein, L, Ashley, D, Singh, M, Hayes, T, Playford, G, Morrissey, O, Thaler, J, Kuehr, T, Greil, R, Pecherstorfer, M, Duck, L, Van Eygen, K, Aoun, M, De Prijck, B, Franke, FA, Barrios, CHE, Mendes, AVA, Serrano, SV, Garcia, RF, Moore, F, Camargo, JFC, Pires, LA, Alves, RS, Radinov, A, Oreshkov, K, Minchev, V, Hubenova, AI, Koynova, T, Ivanov, I, Rabotilova, B, Petrov, PA, Chilingirov, P, Karanikolov, S, Raynov, J, Grimard, D, McNeil, S, Kumar, D, Larratt, LM, Weiss, K, Delage, R, Diaz-Mitoma, FJ, Cano, PO, Couture, F, Carvajal, P, Yepes, A, Torres Ulloa, R, Fardella, P, Caglevic, C, Rojas, C, Orellana, E, Gonzalez, P, Acevedo, A, Galvez, KM, Gonzalez, ME, Franco, S, Restrepo, JG, Rojas, CA, Bonilla, C, Florez, LE, Ospina, AV, Manneh, R, Zorica, R, Vrdoljak, DV, Samarzija, M, Petruzelka, L, Vydra, J, Mayer, J, Cibula, D, Prausova, J, Paulson, G, Ontaneda, M, Palk, K, Vahlberg, A, Rooneem, R, Galtier, F, Postil, D, Lucht, F, Laine, F, Launay, O, Laurichesse, H, Duval, X, Cornely, OA, Camerer, B, Panse, J, Zaiss, M, Derigs, H-G, Menzel, H, Verbeek, M, Georgoulias, V, Mavroudis, D, Anagnostopoulos, A, Terpos, E, Cortes, D, Umanzor, J, Bejarano, S, Galeano, RW, Wong, RSM, Hui, P, Pedrazzoli, P, Ruggeri, L, Aversa, F, Bosi, A, Gentile, G, Rambaldi, A, Contu, A, Marei, L, Abbadi, A, Hayajneh, W, Kattan, J, Farhat, F, Chahine, G, Rutkauskiene, J, Marfil Rivera, LJ, Lopez Chuken, YA, Franco Villarreal, H, Lopez Hernandez, J, Blacklock, H, Lopez, RI, Alvarez, R, Gomez, AM, Quintana, TS, Moreno Larrea, MDC, Zorrilla, SJ, Alarcon, E, Samanez, FCA, Caguioa, PB, Tiangco, BJ, Mora, EM, Betancourt-Garcia, RD, Hallman-Navarro, D, Feliciano-Lopez, LJ, Velez-Cortes, HA, Cabanillas, F, Ganea, DE, Ciuleanu, TE, Ghizdavescu, DG, Miron, L, Cebotaru, CL, Cainap, CI, Anghel, R, Dvorkin, MV, Gladkov, OA, Fadeeva, NV, Kuzmin, AA, Lipatov, ON, Zbarskaya, II, Akhmetzyanov, FS, Litvinov, IV, Afanasyev, BV, Cherenkova, M, Lioznov, D, Lisukov, IA, Smirnova, YA, Kolomietz, S, Halawani, H, Goh, YT, Drgona, L, Chudej, J, Matejkova, M, Reckova, M, Rapoport, BL, Szpak, WM, Malan, DR, Jonas, N, Jung, CW, Lee, DG, Yoon, SS, Lopez Jimenez, J, Duran Martinez, I, Rodriguez Moreno, JF, Solano Vercet, C, de la Camara, R, Batlle Massana, M, Yeh, S-P, Chen, C-Y, Chou, H-H, Tsai, C-M, Chiu, C-H, Siritanaratkul, N, Norasetthada, L, Sriuranpong, V, Seetalarom, K, Akan, H, Dane, F, Ozcan, MA, Ozsan, GH, Kalayoglu Besisik, SF, Cagatay, A, Yalcin, S, Peniket, A, Mullan, SR, Dakhil, KM, Sivarajan, K, Suh, JJ-G, Sehgal, A, Marquez, F, Gomez, EG, Mullane, MR, Skinner, WL, Behrens, RJ, Trevarthe, DR, Mazurczak, MA, Lambiase, EA, Vidal, CA, Anac, SY, Rodrigues, GA, Baltz, B, Boccia, R, Wertheim, MS, Holladay, CS, Zenk, D, Fusselman, W, Wade III, JL, Jaslowsk, AJ, Keegan, J, Robinson, MO, Go, RS, Farnen, J, Amin, B, Jurgens, D, Risi, GF, Jr, Beatty, PG, Naqvi, T, Parshad, S, Hansen, VL, Ahmed, M, Steen, PD, Badarinath, S, Dekker, A, Scouros, MA, Young, DE, Graydon Harker, W, Kendall, SD, Citron, ML, Chedid, S, Posada, JG, Jr, Gupta, MK, Rafiyath, S, Buechler-Price, J, Sreenivasappa, S, Chay, CH, Burke, JM, Young, SE, Mahmood, A, Kugler, JW, Gerstner, G, Fuloria, J, Belman, ND, Geller, R, Nieva, J, Whittenberger, BP, Wong, BMY, Cescon, TP, Abesada-Terk, G, Jr, Guarino, MJ, Zweibach, A, Ibrahim, EN, Takahashi, G, Garrison, MA, Mowat, RB, Choi, BS, Oliff, IA, Singh, J, Guter, KA, Ayrons, K, Rowland, KM, Noga, SJ, Rao, SB, Columbie, A, Nualart, MT, Cecchi, GR, Campos, LT, Mohebtash, M, Flores, MR, Rothstein-Rubin, R, O'Connor, BM, Soori, G, Knapp, M, Miranda, FG, Goodgame, BW, Kassem, M, Belani, R, Sharma, S, Ortiz, T, Sonneborn, HL, Markowitz, AB, Wilbur, D, Meiri, E, Koo, VS, Jhangiani, HS, Wong, L, Sanani, S, Lawrence, SJ, Jones, CM, Murray, C, Papageorgiou, C, Gurtler, JS, Ascensao, JL, Venigalla, ML, D'Andrea, M, De Las Casas, C, Haile, DJ, Qazi, FU, Santander, JL, Thomas, MR, Rao, VP, Craig, M, Garg, RJ, Robles, R, Lyons, RM, Stegemoller, RK, Goel, S, Garg, S, Lowry, P, Lynch, C, Lash, B, Repka, T, Baker, J, Goueli, BS, Campbell, TC, Van Echo, DA, Lee, YJ, Reyes, EA, Senecal, FM, Donnelly, G, Byeff, P, Weiss, R, Reid, T, Roeland, E, Goel, A, Prow, DM, Brandt, DS, Kaplan, HG, Payne, JE, Boeckh, MG, Rosen, PJ, Mena, RR, Khan, R, Betts, RF, Sharp, SA, Morrison, VA, Fitz-Patrick, D, Congdon, J, Erickson, N, Abbasi, R, Henderson, S, Mehdi, A, Wos, EJ, Rehmus, E, Beltzer, L, Tamayo, RA, Mahmood, T, Reboli, AC, Moore, A, Brown, JM, Cruz, J, Quick, DP, Potz, JL, Kotz, KW, Hutchins, M, Chowhan, NM, Devabhaktuni, YD, Braly, P, Berenguer, RA, Shambaugh, SC, O'Rourke, TJ, Conkright, WA, Winkler, CF, Addo, FEK, Duic, JP, High, KP, Kutner, ME, Collins, R, Carrizosa, DR, Perry, DJ, Kailath, E, Rosen, N, Sotolongo, R, Shoham, S, Chen, T, Mullane, Kathleen M ^*, Morrison, Vicki A, Camacho, Luis H, Arvin, Ann, McNeil, Shelly A, Durrand, Jessie, Campbell, Bernadette, Su, Shu-Chih, Chan, Ivan S F, Parrino, Janie, Kaplan, Susan S, Popmihajlov, Zoran, Annunziato, Paula W

المصدر: In The Lancet Infectious Diseases September 2019 19(9):1001-1012

المؤلفون: Sternberg CN; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Davis ID; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Mardiak J; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Szczylik C; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Lee E; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Wagstaff J; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Barrios CH; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Salman P; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Gladkov OA; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Kavina A; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Zarbá JJ; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Chen M; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., McCann L; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Pandite L; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Roychowdhury DF; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC., Hawkins RE; From the Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy; Ludwig Oncology Unit, Austin Hospital, Melbourne, Australia; National Oncological Institute, Klenová, Bratislava, Slovakia; Department of Oncology, Military Institute of Medicine, Warsaw, Poland; Department of Urology, Seoul National University College of Medicine, Seoul, Korea; The South West Wales Cancer Institute, Singleton Hospital, Swansea; Cancer Research UK, Department of Medical Oncology, University of Manchester; Christie Hospital National Health Services Foundation Trust, Manchester, United Kingdom; Oncology Research Unit, Oncology Service, Hospital Sao Lucas, Pontifícia Universidade Católica do Rio Grande do Sol, Porto Alegre, Brazil; Division of Medical Oncology and Hematology, Fundación Arturo López Pérez, Santiago, Chile; Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation; Krankenhaus Heitzing, mit Neurologischem Zentrum Rosenhugel, Vienna, Austria; Centro Médico San Roque, Tucumán, Argentina; GlaxoSmithKline, Collegeville, PA; and GlaxoSmithKline, Research Triangle Park, NC.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Apr 10; Vol. 41 (11), pp. 1957-1964.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Hingorani SR; Fred Hutchinson Cancer Research Center, Seattle, Washington. University of Washington School of Medicine, Seattle, Washington. srh@fhcrc.org., Harris WP; Fred Hutchinson Cancer Research Center, Seattle, Washington. University of Washington School of Medicine, Seattle, Washington., Beck JT; Highlands Oncology Group, Fayetteville, Arkansas., Berdov BA; Medical Radiological Research Center, Obninsk, Russian Federation., Wagner SA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana., Pshevlotsky EM; Omsk Regional Budget Medical Institution: Clinical Oncological Center, Omsk, Russian Federation., Tjulandin SA; Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Russian Federation., Gladkov OA; Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation., Holcombe RF; Icahn School of Medicine at Mt. Sinai, New York, New York., Korn R; Imaging Endpoints, Scottsdale, Arizona., Raghunand N; Moffitt Cancer Center, Tampa, Florida., Dychter S; Halozyme Therapeutics, San Diego, California., Jiang P; Halozyme Therapeutics, San Diego, California., Shepard HM; Halozyme Therapeutics, San Diego, California., Devoe CE; Hofstra North Shore-LIJ School of Medicine, Hempstead, New York.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Jun 15; Vol. 22 (12), pp. 2848-54. Date of Electronic Publication: 2016 Jan 26.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Multicenter Study

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Pancreatic Ductal/*drug therapy , Deoxycytidine/*analogs & derivatives , Hyaluronoglucosaminidase/*therapeutic use , Pancreatic Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Carcinoma, Pancreatic Ductal/pathology ; Deoxycytidine/therapeutic use ; Dexamethasone/therapeutic use ; Disease-Free Survival ; Female ; Humans ; Hyaluronoglucosaminidase/adverse effects ; Hyaluronoglucosaminidase/chemistry ; Hyaluronoglucosaminidase/genetics ; Liver Neoplasms/secondary ; Lung Neoplasms/secondary ; Lymphatic Metastasis/pathology ; Male ; Middle Aged ; Pancreas/pathology ; Pancreatic Neoplasms/pathology ; Polyethylene Glycols/chemistry ; Recombinant Proteins/genetics ; Recombinant Proteins/therapeutic use ; Russia ; Treatment Outcome ; United States ; Gemcitabine

المؤلفون: Vansteenkiste JF; Respiratory Oncology Unit, Department of Respiratory Medicine, University Hospital KU Leuven, Leuven, Belgium. Electronic address: johan.vansteenkiste@uzleuven.be., Cho BC; Yonsei University College of Medicine, Seoul, South Korea., Vanakesa T; North Estonian Regional Hospital, Oncology Department, Tallinn, Estonia., De Pas T; Oncology Unit of Thymic Cancer, Rare Tumors and Sarcomas, Milan, Italy., Zielinski M; Department of Thoracic Surgery, Zakopane, Poland., Kim MS; National Cancer Center, Goyang-si Kyunggi-do, South Korea., Jassem J; Medical University of Gdansk, Gdansk, Poland., Yoshimura M; Hyogo Cancer Center, Akashi City, Hyogo, Japan., Dahabreh J; Athens Medical Centre, Marousi, Greece., Nakayama H; Kanagawa Cancer Center, Yokohama City, Japan., Havel L; Department of Pneumology and Thoracic Surgery, Prague, Czech Republic., Kondo H; Shizuoka Cancer Center, Tokyo, Japan., Mitsudomi T; Aichi Cancer Center Hospital 1-1, Aichi, Japan., Zarogoulidis K; Pulmonary Clinic, G Papanikolaou General Hospital of Thessaloniki, Aristotle University, Thessaloniki, Greece., Gladkov OA; Regional Oncology Dispensary Medgorodok, Chelyabinsk, Russia., Udud K; Korányi National Institute of Pulmonology, Budapest, Hungary., Tada H; Osaka City General Hospital, Osaka, Japan., Hoffman H; Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany., Bugge A; Oslo University Hospital, Rikshospitalet, Oslo, Norway., Taylor P; University Hospital of South Manchester, Manchester, UK., Gonzalez EE; Hospital Central de Asturias, Oviedo, Spain., Liao ML; Shanghai Chest Hospital, Shanghai, China., He J; The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China., Pujol JL; Arnaud de Villeneuve Hospital, Montpellier, France., Louahed J; GSK Vaccines, Rixensart, Belgium., Debois M; GSK Vaccines, Rixensart, Belgium., Brichard V; GSK Vaccines, Rixensart, Belgium., Debruyne C; GSK Vaccines, Rixensart, Belgium., Therasse P; GSK Vaccines, Rixensart, Belgium., Altorki N; Joan and Sanford I Weill Medical College of Cornell University, New York, NY, USA.

المصدر: The Lancet. Oncology [Lancet Oncol] 2016 Jun; Vol. 17 (6), pp. 822-835. Date of Electronic Publication: 2016 Apr 27.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy*, Antigens, Neoplasm/*immunology , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Immunoconjugates/*therapeutic use , Lung Neoplasms/*drug therapy , Neoplasm Proteins/*immunology , Neoplasm Recurrence, Local/*drug therapy, Aged ; Antigens, Neoplasm/metabolism ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Chemotherapy, Adjuvant ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/immunology ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Proteins/metabolism ; Neoplasm Recurrence, Local/immunology ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prognosis ; Survival Rate

المؤلفون: Gladkov OA; Chelyabinsk Regional Clinical Oncology Dispensary, 42 Blukhera str, Chelyabinsk, 454087, Russian Federation. gladkov_o@rambler.ru., Buchner A; Merckle GmbH, Graf-Arco-Strasse 3, 89079, Ulm, Germany., Bias P; Teva Ratiopharm, Graf-Arco-Strasse 3, 89079, Ulm, Germany., Müller U; Teva Ratiopharm, Graf-Arco-Strasse 3, 89079, Ulm, Germany., Elsässer R; Teva Ratiopharm, Graf-Arco-Strasse 3, 89079, Ulm, Germany.

المصدر: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 Jan; Vol. 24 (1), pp. 395-400. Date of Electronic Publication: 2015 Jun 20.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9302957 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-7339 (Electronic) Linking ISSN: 09414355 NLM ISO Abbreviation: Support Care Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Breast Neoplasms/*drug therapy, Administration, Cutaneous ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chemotherapy-Induced Febrile Neutropenia/etiology ; Cost of Illness ; Critical Care/statistics & numerical data ; Docetaxel ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Filgrastim ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Humans ; Length of Stay/statistics & numerical data ; Middle Aged ; Polyethylene Glycols ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/adverse effects ; Risk Factors ; Taxoids/administration & dosage ; Taxoids/adverse effects

المؤلفون: Volovat C; Centrul de Oncologie Medicala, Vasile Conta 2 Str, 700106 Iasi, Romania., Bondarenko IM; Dnipropetrovsk State Medical Academy, City Clinical Hospital, N 4, 31, Glizhnaya Str, Dnipropetrovsk, 49102 Ukraine., Gladkov OA; Chelyabinsk Regional Clinical Oncology Dispensary, 42, Blukhera Str., Chelyabinsk, 454087 Russia., Elsässer R; Teva Ratiopharm, Merckle GmbH, Graf-Arco-Strasse 3, 89079 Ulm, Germany., Buchner A; Teva Ratiopharm, Merckle GmbH, Graf-Arco-Strasse 3, 89079 Ulm, Germany., Bias P; Teva Ratiopharm, Merckle GmbH, Graf-Arco-Strasse 3, 89079 Ulm, Germany., Müller U; Teva Pharmaceuticals, Inc., Graf-Arco-Strasse 3, 89079 Ulm, Germany.

المصدر: SpringerPlus [Springerplus] 2015 Jul 03; Vol. 4, pp. 316. Date of Electronic Publication: 2015 Jul 03 (Print Publication: 2015).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: SpringerPlus Country of Publication: Switzerland NLM ID: 101597967 Publication Model: eCollection Cited Medium: Print ISSN: 2193-1801 (Print) Linking ISSN: 21931801 NLM ISO Abbreviation: Springerplus Subsets: PubMed not MEDLINE

المؤلفون: Clemens MR; Innere Medizin I, Klinikum Mutterhaus de Borromaerinnen GmbH, Trier, Germany, Clemens@mutterhaus.de., Gladkov OA, Gartner E, Vladimirov V, Crown J, Steinberg J, Jie F, Keating A

المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2015 Jan; Vol. 149 (1), pp. 171-9. Date of Electronic Publication: 2014 Dec 30.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Breast Neoplasms/*drug therapy , Imidazoles/*administration & dosage , Naphthoquinones/*administration & dosage , Taxoids/*administration & dosage, Adult ; Aged ; Breast Neoplasms/pathology ; Disease-Free Survival ; Docetaxel ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Humans ; Imidazoles/adverse effects ; Lymphatic Metastasis ; Middle Aged ; Naphthoquinones/adverse effects ; Receptor, ErbB-2/genetics ; Taxoids/adverse effects ; Treatment Outcome

المؤلفون: Volovat C; Centrul de Oncologie Medicala, Iasi, Romania., Gladkov OA; Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russia., Bondarenko IM; Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine., Barash S; Teva Biopharmaceuticals, Inc, Rockville, MD., Buchner A; Teva ratiopharm, Ulm, Germany., Bias P; Teva ratiopharm, Ulm, Germany., Adar L; Teva Pharmaceuticals, Inc, Netanya, Israel., Avisar N; Teva Pharmaceuticals, Inc, Netanya, Israel. Electronic address: noa.avisar@teva.co.il.

المصدر: Clinical breast cancer [Clin Breast Cancer] 2014 Apr; Vol. 14 (2), pp. 101-8. Date of Electronic Publication: 2013 Oct 25.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms/*drug therapy , Granulocyte Colony-Stimulating Factor/*therapeutic use , Polyethylene Glycols/*chemistry , Recombinant Fusion Proteins/*therapeutic use , Serum Albumin/*chemistry, Breast Neoplasms/secondary ; Double-Blind Method ; Female ; Filgrastim ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Recombinant Proteins/therapeutic use ; Safety ; Serum Albumin/therapeutic use ; Serum Albumin, Human ; Treatment Outcome

المؤلفون: Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P

المصدر: BMC cancer [BMC Cancer] 2013 Aug 14; Vol. 13, pp. 386. Date of Electronic Publication: 2013 Aug 14.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Granulocyte Colony-Stimulating Factor/*therapeutic use , Neutropenia/*chemically induced, Aged ; Breast Neoplasms/pathology ; Docetaxel ; Double-Blind Method ; Doxorubicin/administration & dosage ; Female ; Filgrastim ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Polyethylene Glycols ; Prognosis ; Recombinant Proteins/therapeutic use ; Taxoids/administration & dosage

المؤلفون: Sternberg CN; Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. cstern@mclink.it, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2013 Apr; Vol. 49 (6), pp. 1287-96. Date of Electronic Publication: 2013 Jan 12.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Renal Cell/*drug therapy , Kidney Neoplasms/*drug therapy , Pyrimidines/*therapeutic use , Sulfonamides/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Angiogenesis Inhibitors/therapeutic use ; Carcinoma, Renal Cell/pathology ; Cross-Over Studies ; Diarrhea/chemically induced ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Hypertension/chemically induced ; Indazoles ; Kaplan-Meier Estimate ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Pyrimidines/adverse effects ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Sulfonamides/adverse effects ; Treatment Outcome